Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
Ulrike Garske‐Román(Uppsala University Hospital), Donald Granberg(Uppsala University Hospital), Hans Lundqvist(Uppsala University), Silvia Johansson(Uppsala University), Anders Sundin, Per Hellman(Uppsala University Hospital), Mattias Sandström(Uppsala University Hospital), Staffan Welin(Uppsala University), Katarzyna Fröss Baron(Uppsala University), Barbro Eriksson, Tanweera Khan(Uppsala University), Lars Lundin(Uppsala University)
Cited by 249
Related Papers
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863